American Portfolios Advisors Corbus Pharmaceuticals Holdings, Inc. Transaction History

American Portfolios Advisors

  • $2.36 Trillion
  • Q3 2022

A detailed history of American Portfolios Advisors transactions in Corbus Pharmaceuticals Holdings, Inc. stock. As of the latest transaction made, American Portfolios Advisors holds 2,312 shares of CRBP stock, worth $41,985. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,312
Holding current value
$41,985
% of portfolio
0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Mar 17, 2023
BUY
$0.17 - $5.31 $393 - $12,276
2,312 New
2,312 $381,000
Q2 2022

Mar 20, 2023
SELL
$0.21 - $0.53 $21 - $53
-100 Reduced 4.33%
2,212 $558,000
Q1 2022

Mar 21, 2023
SELL
$0.32 - $0.67 $32 - $67
-100 Reduced 4.33%
2,212 $1.18 Million
Q4 2021

Mar 21, 2023
SELL
$0.6 - $1.11 $60 - $111
-100 Reduced 4.33%
2,212 $1.36 Million
Q3 2021

Mar 22, 2023
SELL
$1.01 - $1.82 $101 - $182
-100 Reduced 4.33%
2,212 $2.26 Million
Q2 2021

Mar 22, 2023
SELL
$1.39 - $2.21 $139 - $221
-100 Reduced 4.33%
2,212 $4.05 Million
Q1 2021

Mar 22, 2023
SELL
$1.27 - $3.42 $127 - $342
-100 Reduced 4.33%
2,212 $4.36 Million
Q4 2020

Mar 22, 2023
SELL
$0.94 - $1.89 $94 - $189
-100 Reduced 4.33%
2,212 $2.77 Million
Q3 2020

Mar 22, 2023
SELL
$1.5 - $9.38 $150 - $938
-100 Reduced 4.33%
2,212 $3.98 Million
Q1 2020

Mar 24, 2023
BUY
$3.44 - $7.21 $1,720 - $3,605
500 Added 21.63%
2,812 $14.7 Million
Q4 2019

Mar 24, 2023
SELL
$4.29 - $5.64 $429 - $564
-100 Reduced 4.33%
2,212 $12.1 Million
Q3 2019

Mar 24, 2023
SELL
$4.87 - $7.08 $487 - $708
-100 Reduced 4.33%
2,212 $10.8 Million

Others Institutions Holding CRBP

# of Institutions
4
Shares Held
38.7K
Call Options Held
0
Put Options Held
0
View Full List

About Corbus Pharmaceuticals Holdings, Inc.

CRBP Quotes by TradingView
  • Ticker CRBP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 125,268,000
  • Market Cap $2.27B
  • Description
  • Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an...
More about CRBP
Track This Portfolio

Track American Portfolios Advisors Portfolio

Follow American Portfolios Advisors and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of American Portfolios Advisors, based on Form 13F filings with the SEC.

News

Stay updated on American Portfolios Advisors with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email